Clinical Trials Contact Us Careers Home Search About Us Our Company Pioneers in Rare Disease Established in 1997, BioMarin is a world leader in developing and commercializing first- or best-in-class therapies for rare genetic diseases. We take pride in going where the science leads us, pioneering breakthrough treatments for debilitating and life-threatening conditions where we can significantly improve upon the current standard of care. Our culture revolves around the ethos that no disease should go untreated, and our people are driven to discover, develop, and commercialize medicines that give patients, their families, and their caregivers hope where there was little or none. We fuel our R&D engine by looking for opportunities that align with our strengths and competencies. And we relentlessly pursue exciting, early-stage science that has the potential to change the course of disease. Voted one of America’s Best Midsize Employer by Forbes in 2019, our employees feel connected to their work at BioMarin because they believe in our purpose: the patient. The passion and dedication that our employees bring to work each day is a testament to the inspiration our patients provide, and the knowledge of the impact we can make in their lives. BioMarin at a Glance Headquarters San Rafael, California Founded 1997 Chairman and CEO Jean-Jacques Bienaimé Employees 3,000 Ticker NASDAQ: BMRN Revenue 2019 $1.7 billion Net Income (Loss) 2019 ($23.8 million) Focus Rare genetic diseases Products PALYNZIQ® (pegvaliase-pqpz) Injection self-administered enzyme substitution therapy for PKU Brineura® (cerliponase alfa) for CLN2 Disease Vimizim® (elosulfase alfa) for MPS IVA Kuvan® (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution for PKU Naglazyme® (galsulfase) for MPS VI Aldurazyme® (laronidase) for MPS I VOXZOGO® (vosoritide) Injection for Achondroplasia Clinical Pipeline Valoctocogene Roxaparvovec (BMN 270) AAV-Factor VIII Vector for Hemophilia A BMN 307 AAV Gene Therapy for PKU BMN 331 AAV Gene Therapy for Hereditary Angiodema Partners Genzyme Corporation OUR HISTORY More than twenty years of making a big difference in rare patient populations. Learn More OUR PIPELINE We take on the biggest challenges in rare disease. Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. View Now Leadership Team Our management team represents a dynamic cross section of business, clinical and biotechnical expertise. Learn More Diversity, Equity & Inclusion We value diverse perspectives from a broad spectrum of backgrounds, education, personalities, skill sets, experiences, and knowledge. Learn More Home › Our Company › About Us Home Navigate Our Motivation Our Science Our Treatments Our Company Investors & Media About Our History Our Products Our Pipeline Leadership Team Board of Directors Diversity, Equity & Inclusion Contact Global Contact Information Our Locations Report a Product Complaint Report Adverse Event Publication Data Request Funding & Support Connect Careers LinkedIn Facebook Instagram YouTube Privacy Policy Terms of Use Site Map Supplier Information Slavery Act Statement Glossary Contact Us © 2021 BioMarin. All rights reserved. You may delete or block cookies by accessing your preferences. For more information, please see our Privacy Policy and Terms and Conditions. By using this website, you consent to our use of cookies.Accept